vs
阿普塔集团（ATR）与Fortive（FTV）财务数据对比。点击上方公司名可切换其他公司
Fortive的季度营收约是阿普塔集团的1.1倍（$1.0B vs $962.7M），阿普塔集团净利率更高（7.7% vs 5.4%，领先2.4%），阿普塔集团同比增速更快（13.5% vs -33.1%），Fortive自由现金流更多（$153.1M vs $96.9M），过去两年阿普塔集团的营收复合增速更高（2.6% vs -19.5%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
Fortive是总部位于美国华盛顿州埃弗里特的工业科技集团，专注于提供互联工作流解决方案所需的核心技术，研发、生产及销售专业工程类产品、软件与服务，旗下业务分为智能运营解决方案、精密技术、先进医疗解决方案三大战略板块。
ATR vs FTV — 直观对比
营收规模更大
FTV
是对方的1.1倍
$962.7M
营收增速更快
ATR
高出46.6%
-33.1%
净利率更高
ATR
高出2.4%
5.4%
自由现金流更多
FTV
多$56.2M
$96.9M
两年增速更快
ATR
近两年复合增速
-19.5%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $962.7M | $1.0B |
| 净利润 | $74.3M | $55.0M |
| 毛利率 | — | 63.2% |
| 营业利润率 | 11.0% | 15.5% |
| 净利率 | 7.7% | 5.4% |
| 营收同比 | 13.5% | -33.1% |
| 净利润同比 | -26.4% | -75.2% |
| 每股收益（稀释后） | $1.13 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRFTV
| Q4 25 | $962.7M | — | ||
| Q3 25 | $961.1M | $1.0B | ||
| Q2 25 | $966.0M | $1.5B | ||
| Q1 25 | $887.3M | $1.5B | ||
| Q4 24 | $848.1M | $1.6B | ||
| Q3 24 | $909.3M | $1.5B | ||
| Q2 24 | $910.1M | $1.6B | ||
| Q1 24 | $915.4M | $1.5B |
净利润ATRFTV
| Q4 25 | $74.3M | — | ||
| Q3 25 | $127.9M | $55.0M | ||
| Q2 25 | $111.7M | $166.6M | ||
| Q1 25 | $78.8M | $171.9M | ||
| Q4 24 | $100.9M | $208.8M | ||
| Q3 24 | $100.0M | $221.6M | ||
| Q2 24 | $90.5M | $195.1M | ||
| Q1 24 | $83.1M | $207.4M |
毛利率ATRFTV
| Q4 25 | — | — | ||
| Q3 25 | — | 63.2% | ||
| Q2 25 | — | 59.0% | ||
| Q1 25 | — | 59.8% | ||
| Q4 24 | — | 60.3% | ||
| Q3 24 | — | 60.0% | ||
| Q2 24 | — | 59.8% | ||
| Q1 24 | — | 59.3% |
营业利润率ATRFTV
| Q4 25 | 11.0% | — | ||
| Q3 25 | 14.2% | 15.5% | ||
| Q2 25 | 14.9% | 14.6% | ||
| Q1 25 | 12.8% | 15.8% | ||
| Q4 24 | 14.2% | 19.0% | ||
| Q3 24 | 15.2% | 19.3% | ||
| Q2 24 | 13.8% | 19.4% | ||
| Q1 24 | 12.2% | 19.8% |
净利率ATRFTV
| Q4 25 | 7.7% | — | ||
| Q3 25 | 13.3% | 5.4% | ||
| Q2 25 | 11.6% | 11.0% | ||
| Q1 25 | 8.9% | 11.7% | ||
| Q4 24 | 11.9% | 12.9% | ||
| Q3 24 | 11.0% | 14.4% | ||
| Q2 24 | 9.9% | 12.6% | ||
| Q1 24 | 9.1% | 13.6% |
每股收益（稀释后）ATRFTV
| Q4 25 | $1.13 | — | ||
| Q3 25 | $1.92 | $0.16 | ||
| Q2 25 | $1.67 | $0.49 | ||
| Q1 25 | $1.17 | $0.50 | ||
| Q4 24 | $1.48 | $0.60 | ||
| Q3 24 | $1.48 | $0.63 | ||
| Q2 24 | $1.34 | $0.55 | ||
| Q1 24 | $1.23 | $0.58 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.5M | $430.8M |
| 总债务越低越好 | $1.1B | $3.3B |
| 股东权益账面价值 | $2.7B | $6.5B |
| 总资产 | $5.3B | $11.9B |
| 负债/权益比越低杠杆越低 | 0.43× | 0.51× |
8季度趋势，按日历期对齐
现金及短期投资ATRFTV
| Q4 25 | $409.5M | — | ||
| Q3 25 | $264.8M | $430.8M | ||
| Q2 25 | $169.8M | $1.8B | ||
| Q1 25 | $136.8M | $892.1M | ||
| Q4 24 | $226.2M | $813.3M | ||
| Q3 24 | $327.9M | $811.3M | ||
| Q2 24 | $223.9M | $644.1M | ||
| Q1 24 | $201.1M | $704.6M |
总债务ATRFTV
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | $3.3B | ||
| Q2 25 | $535.1M | $4.8B | ||
| Q1 25 | $561.2M | $3.9B | ||
| Q4 24 | $688.1M | $3.7B | ||
| Q3 24 | $822.7M | $3.9B | ||
| Q2 24 | $681.5M | $3.8B | ||
| Q1 24 | $680.4M | $3.9B |
股东权益ATRFTV
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.8B | $6.5B | ||
| Q2 25 | $2.7B | $10.4B | ||
| Q1 25 | $2.5B | $10.2B | ||
| Q4 24 | $2.5B | $10.2B | ||
| Q3 24 | $2.5B | $10.6B | ||
| Q2 24 | $2.4B | $10.5B | ||
| Q1 24 | $2.3B | $10.5B |
总资产ATRFTV
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.1B | $11.9B | ||
| Q2 25 | $4.9B | $18.2B | ||
| Q1 25 | $4.5B | $17.1B | ||
| Q4 24 | $4.4B | $17.0B | ||
| Q3 24 | $4.6B | $17.5B | ||
| Q2 24 | $4.5B | $17.3B | ||
| Q1 24 | $4.4B | $17.5B |
负债/权益比ATRFTV
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | 0.51× | ||
| Q2 25 | 0.20× | 0.46× | ||
| Q1 25 | 0.22× | 0.38× | ||
| Q4 24 | 0.28× | 0.36× | ||
| Q3 24 | 0.32× | 0.37× | ||
| Q2 24 | 0.28× | 0.36× | ||
| Q1 24 | 0.29× | 0.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $183.7M | $164.4M |
| 自由现金流经营现金流 - 资本支出 | $96.9M | $153.1M |
| 自由现金流率自由现金流/营收 | 10.1% | 14.9% |
| 资本支出强度资本支出/营收 | 9.0% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.47× | 2.99× |
| 过去12个月自由现金流最近4个季度 | $299.6M | $1.1B |
8季度趋势，按日历期对齐
经营现金流ATRFTV
| Q4 25 | $183.7M | — | ||
| Q3 25 | $177.6M | $164.4M | ||
| Q2 25 | $126.0M | $311.2M | ||
| Q1 25 | $82.7M | $241.7M | ||
| Q4 24 | $178.2M | $502.2M | ||
| Q3 24 | $229.3M | $459.0M | ||
| Q2 24 | $143.6M | $308.9M | ||
| Q1 24 | $92.3M | $256.7M |
自由现金流ATRFTV
| Q4 25 | $96.9M | — | ||
| Q3 25 | $114.3M | $153.1M | ||
| Q2 25 | $62.5M | $274.5M | ||
| Q1 25 | $25.9M | $215.0M | ||
| Q4 24 | $112.2M | $465.2M | ||
| Q3 24 | $162.7M | $431.2M | ||
| Q2 24 | $75.4M | $279.7M | ||
| Q1 24 | $16.7M | $230.3M |
自由现金流率ATRFTV
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.9% | 14.9% | ||
| Q2 25 | 6.5% | 18.1% | ||
| Q1 25 | 2.9% | 14.6% | ||
| Q4 24 | 13.2% | 28.7% | ||
| Q3 24 | 17.9% | 28.1% | ||
| Q2 24 | 8.3% | 18.0% | ||
| Q1 24 | 1.8% | 15.1% |
资本支出强度ATRFTV
| Q4 25 | 9.0% | — | ||
| Q3 25 | 6.6% | 1.1% | ||
| Q2 25 | 6.6% | 2.4% | ||
| Q1 25 | 6.4% | 1.8% | ||
| Q4 24 | 7.8% | 2.3% | ||
| Q3 24 | 7.3% | 1.8% | ||
| Q2 24 | 7.5% | 1.9% | ||
| Q1 24 | 8.3% | 1.7% |
现金转化率ATRFTV
| Q4 25 | 2.47× | — | ||
| Q3 25 | 1.39× | 2.99× | ||
| Q2 25 | 1.13× | 1.87× | ||
| Q1 25 | 1.05× | 1.41× | ||
| Q4 24 | 1.77× | 2.41× | ||
| Q3 24 | 2.29× | 2.07× | ||
| Q2 24 | 1.59× | 1.58× | ||
| Q1 24 | 1.11× | 1.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
FTV
| Advanced Healthcare Solutions | $328.3M | 32% |
| Industrial Manufacturing | $287.9M | 28% |
| Energy And Infrastructure | $166.7M | 16% |
| Government | $88.0M | 9% |
| Retail | $82.7M | 8% |
| Other Direct End Markets | $79.6M | 8% |
